Article
The Advantages of Artificial Intelligence for Risk-Based Monitoring in Clinical Trials
Learn how AI and machine learning can strengthen risk-based quality management by identifying patterns, anomalies, and emerging risks across clinical trial data—helping sponsors move toward more proactive trial oversight.
About this article
What's inside
Learn how AI and machine learning can strengthen risk-based quality management by identifying patterns, anomalies, and emerging risks across clinical trial data—helping sponsors move toward more proactive trial oversight.
Key takeaways
What you'll learn
- How AI/ML enhances risk-based monitoring and predictive risk assessment
- How sponsors can identify site, patient, operational, and data-quality risks earlier
- How AI-enabled RBQM supports faster data review and improved protocol compliance
- Practical examples of AI/ML-powered risk monitoring in clinical trials
Explore how AI/ML can help clinical teams detect risks earlier, strengthen trial oversight, and support a more proactive approach to RBQM.
About the author
Moulik Shah
Founder & CEO, Maxis AI
Moulik Shah is the Founder and CEO of Maxis AI, an enterprise agentic AI platform for the pharmaceutical and life sciences industry. With over 20 years of experience in healthcare technology, he has spent the majority of his career helping pharma, biotech, and CRO organizations modernize clinical trials through data and AI. He is a Forbes Technology Council contributor, writing on artificial intelligence and enterprise innovation.
Explore our AI Workforce Platform
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.